Mianserin HCl is inverse agonist of H1 receptor and can be act as a psychoactive agent of the tetracyclic antidepressant.

Product information

CAS Number: 21535-47-7

Molecular Weight: 300.83

Formula: C18H21ClN2

Synonym:

ORG GB-94 HCl

Chemical Name: 2-methyl-1,2,3,4,10,14b-hexahydrodibenzo[c,f]pyrazino[1,2-a]azepine hydrochloride

Smiles: Cl.CN1CCN2C(C1)C1=CC=CC=C1CC1=CC=CC=C21

InChiKey: YNPFMWCWRVTGKJ-UHFFFAOYSA-N

InChi: InChI=1S/C18H20N2.ClH/c1-19-10-11-20-17-9-5-3-7-15(17)12-14-6-2-4-8-16(14)18(20)13-19;/h2-9,18H,10-13H2,1H3;1H

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 50 mg/mL (166.21 mM; Need ultrasonic)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Mianserin (2 mg/kg s.c.) causes a modest increase of DOPAC levels up to about 30% above base-line, which is statistically significant when compared to saline. Mianserin increases extracellular norepinephnne, but a comparison with desipramine and idazoxan showed that both NE reuptake inhibition and alpha-2 autoreceptor blockade contributed to the mianserin-induced increase in extracellular norepinephnne. [1] Mianserin and eltoprazine displays opposite effects in the elevated plus-maze: Mianserin induces anxiolytic-like effects, while eltoprazine shows anxiogenic-like ones. Mianserin treatment induces a decrease in the number of these sites, while eltoprazine treatment results in an increase. [2]

In Vivo:

Mianserin, which has a small or no effect in noradrenaline (NA) reuptake but may enhance release by blocking presynaptic inhibition mediated by alpha 2-adrenoceptors, induced regeneration of catecholamine fibers in the rat cerebral cortex. [3] Mianserin attenuates the effects of both m-CPP and SKF 38393 in neonatal 6-OHDA-lesioned rats, suggesting that DA agonist effects are mediated by 5-HT neurochemical systems. [4] Mianserin (10 mg/kg, SC) dose-dependently increases up to about 6 times extracellular dopamine in the medial prefrontal cortex of the rat. Mianserin also dose-dependently increases extracellular noradrenaline in the prefrontal cortex. [5]

References:

1. de Boer TH, et al. J Pharmacol Exp Ther,?996, 277(2), 852-860.
2. Rocha B, et al. Eur J Pharmacol,?994, 262(1-2), 125-131.
3. Nakamura S, et al. Neuroreport,?991, 2(9), 525-528.
4. Plech A, et al. Psychopharmacology (Berl),1995, 119(4), 466-473.
5. Tanda G, et al. Psychopharmacology (Berl),1996, 123(2), 127-130.

Products are for research use only. Not for human use.